secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001551152-24-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q1 adjusted EPS $2.31 (-6.1% YoY); raises 2024 guidance; CEO succession
------------------------------------------------------------------------------

- Q1 revenue $12.31B (+0.7% reported, +1.6% operational); GAAP EPS $0.77, adjusted EPS $2.31.
- Immunology revenue $5.371B (-3.9%) on Humira erosion; Skyrizi +47.6%, Rinvoq +59.3%.
- Oncology +9% to $1.543B; Neuroscience +15.9% to $1.965B; Aesthetics -4% to $1.249B.
- Raises 2024 adjusted EPS guidance to $11.13-$11.33 from $10.97-$11.17; includes $0.08 IPR&D impact.
- CEO succession: Robert Michael to become CEO July 1; Richard Gonzalez becomes executive chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/0001551152-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000016/abbv-20240426.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer